Novartis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.

About NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. 

CEO
Vasant Narasimhan
CEOVasant Narasimhan
Employees
75,267
Employees75,267
Headquarters
Basel, Basel-Stadt (Basle Town)
HeadquartersBasel, Basel-Stadt (Basle Town)
Founded
1996
Founded1996
Employees
75,267
Employees75,267

NVS Key Statistics

Market cap
336.33B
Market cap336.33B
Price-Earnings ratio
30.88
Price-Earnings ratio30.88
Dividend yield
1.90%
Dividend yield1.90%
Average volume
2.30M
Average volume2.30M
High today
$163.11
High today$163.11
Low today
$159.36
Low today$159.36
Open price
$159.43
Open price$159.43
Volume
1.89M
Volume1.89M
52 Week high
$170.46
52 Week high$170.46
52 Week low
$123.24
52 Week low$123.24

NVS News

Seeking Alpha 33m
Novartis is said to be abandoning Ionis heart drug after late-stage trial setback

Novartis (NVS) is largely abandoning the development of a heart disease therapy discovered by Ionis Pharmaceuticals (IONS) after the RNA-targeting therapy faile...

Novartis is said to be abandoning Ionis heart drug after late-stage trial setback
Investing.com 2h
Novartis shelves potential blockbuster pelacarsen as landmark study fails - Investing.com

...

Novartis shelves potential blockbuster pelacarsen as landmark study fails - Investing.com
Seeking Alpha 2d
Novartis slips amid safety concerns tied to Zolgensma

Novartis (NVS) ADRs fell on Thursday after patient advocates highlighted safety concerns potentially linked to its gene therapy, Zolgensma, including nine cases...

Novartis slips amid safety concerns tied to Zolgensma

Analyst ratings

63%

of 8 ratings
Buy
62.5%
Hold
37.5%
Sell
0%

More NVS News

The Motley Fool 4d
Novartis: 3 Key Takeaways for Long-Term Investors

On its third-quarter 2026 earnings call, held on Oct. 27, 2026, Novartis (NVS -1.40%) raised its full-year 2026 core operating income guidance after delivering...

Novartis: 3 Key Takeaways for Long-Term Investors

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.